AllSci News
Lilly Invests $1.9B in Repertoire's DECODE Platform for Precision Autoimmune Therapy
Lilly Taps Repertoire's DECODE Platform for Tolerizing Autoimmune Therapies in USD 1.9B Deal Eli Lil...
Tenpoint Therapeutics’ Yuvezzi gets FDA approval as first dual-agent eye drop for presbyopia
UK-based Tenpoint Therapeutics Ltd revealed that the US FDA has issued an approval to Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%…
UVA and AstraZeneca sign master research collaboration, C. difficile first target
The University of Virginia (UVA) announced the signing of a Master Research Collaboration Agreement with global biopharmaceutical company AstraZeneca to streamline and…
CalciMedica halts Phase II kidney injury study for Auxora due to safety concerns
CalciMedica, Inc., a specialist in calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases, called a halt to a…
Genprex secures new IP for TUSC2 gene therapy in PD-(L)1 combo regimens
Gene therapy specialist Genprex, Inc. announced US Patent and Trademark Office (USPTO) award of a new patent covering the use of its…
Regenxbio slapped with clinical hold on gene therapy programs after tumor safety signal
Regenxbio Inc. (Nasdaq: RGNX) announced that the US FDA placed clinical holds on two investigational gene therapy programs targeting ultra-rare mucopolysaccharidosis (MPS)…
Boehringer Ingelheim’s apecotrep shows proteinuria reduction in Phase II FSGS trial
Boehringer Ingelheim announced positive results from a global Phase II study of apecotrep (BI 764198), an investigational, oral TRPC6 inhibitor, in patients…
Seamless Therapeutics, Lilly form USD 1.1b partnership on recombinase gene editing for hearing loss
Germany-based biotech Seamless Therapeutics and Eli Lilly and Co., entered into a global strategic research collaboration and licensing agreement to jointly develop…
Stellular Bio closes Series 1 financing to advance regenerative biologic therapy into clinic
Stellular Bio, a Watertown, Massachusetts-based biotechnology company focused on developing platelet-derived regenerative biologic (PRB) therapeutics for ocular surface diseases, announced the completion…
US FDA expands Darzalex Faspro approval to frontline myeloma
The US FDA issued a new approval to Johnson & Johnson’s Darzalex Faspro (daratumumab and hyaluronidase-fihj), allowing use in combination with Velcade…
TRex Bio gets USD 50m Series B support for Deep Biology platform
TRex Bio, Inc. (TRexBio), a clinical-stage biotechnology company headquartered in South San Francisco, California, has closed an oversubscribed USD 50 million financing…
Intellia’s CRISPR therapy Phase III to continue after FDA lifts clinical hold
Intellia Therapeutics revealed that the US FDA has lifted the clinical hold on its MAGNITUDE-2 Phase III trial for nexiguran ziclumeran (nex-z),…
Insilico signs latest AI drug development collaboration with Qilu Pharma
Insilico Medicine announced a strategic collaboration and licensing agreement with Qilu Pharmaceutical to jointly develop small molecule inhibitors, focusing on specific targets…
Cardiff Oncology posts Phase II data for onvansertib in mCRC, to push for Phase III
San Diego-based biotech Cardiff Oncology announced a positive clinical update from its ongoing randomized Phase II CRDF-001 trial evaluating onvansertib in patients…
Roche’s CT-388 delivers robust weight-loss outcomes in Phase II obesity study
Swiss drugmaker Roche announced positive topline Phase II data for its once-weekly GLP-1/GIP receptor agonist CT-388, supporting the drug candidate as it…
The AllSci Brief
Free, systematic R&D and deal news. Daily.